在瘤疾病中使用类似葡萄糖-1受体激活剂
Lisan Ji1, Xianzhen He2, Xinwen Min1
1Sinopharm Dongfeng General Hospital (Hubei Clinical Research Center of Hypertension), Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, China.
类似葡萄糖-1受体激动剂 (GLP-1RAs) 显示出超出糖尿病管理的前景. 本综述探讨了它们在癌症预防和治疗中的潜在作用,通过影响细胞生长和存活.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 是已确立的2型糖尿病治疗方法.
- GLP-1RAs表现出性作用,包括血糖控制,抗炎,减肥和降脂特性.
- 新出现的证据表明GLP-1RAs影响细胞增殖和存活,暗示在瘤疾病中的作用.
研究的目的:
- 审查GLP-1RAs对瘤发生和进展的潜在影响.
- 探索使用GLP-1RAs进行癌症预防和治疗的新型治疗策略.
主要方法:
- 临床前和临床研究的文献综述.
- 对GLP-1RA对细胞增殖,细胞亡和瘤模型的影响数据的分析.
- 综合关于GLP-1RAs对各种瘤疾病的影响的发现.
主要成果:
- GLP-1RAs对与瘤发生相关的细胞机制表现出多方面的影响.
- 有证据表明GLP-1RAs在调节瘤微环境方面可能发挥作用.
- 具体研究表明GLP-1RAs在不同癌症类型的不同影响.
结论:
- GLP-1RA可能为癌症预防和治疗策略提供新的途径.
- 需要进一步的研究来阐明GLP-1RAs在瘤学的精确机制和临床实用性.
- 准GLP-1受体是治疗瘤疾病的潜在治疗标.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Hypoglycemia and Glucagon
Oral Hypoglycemic Agents: Glinides
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Oral Hypoglycemic Agents: Biguanides and Glitazones
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
